1101 Results

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Abou-Alfa
    Abou-Alfa
  4. Yaeger
    Yaeger
  5. O'Reilly
    O'Reilly
  6. Paik
    Paik
  7. Rosenberg
    Rosenberg
  8. Hellmann
    Hellmann
  9. Saltz
    Saltz
  10. Wolchok
    Wolchok

Groups

  1. Department of Medicine (975)
  2. Solid Tumor Oncology Division (929)
  3. Gastrointestinal Oncology Service (246)
  4. Genitourinary Oncology Service (222)
  5. Thoracic Oncology (197)
  6. GSK Faculty (108)
  7. Hematologic Malignancies, Division of (90)
  8. Gynecology Disease Management Team (85)
  9. Breast Medicine Service (82)
  10. Survivorship Research (81)
  1. "Annals of Oncology"
  2. "Oxford University Press"
  3. "Meeting abstract"
Formats
  1. Meeting Abstract (1101)
Groups
  1. Department of Medicine (975)
  2. Solid Tumor Oncology Division (929)
  3. Gastrointestinal Oncology Service (246)
  4. Genitourinary Oncology Service (222)
  5. Thoracic Oncology (197)
  6. GSK Faculty (108)

More Groups

People
  1. Alexander Drilon (69)
  2. Robert Motzer (60)
  3. Ghassan Abou-Alfa (48)
  4. Rona Yaeger (32)
  5. Yelena Janjigian (32)
  6. Eileen O'Reilly (31)

More People

Years
  1. 2023 (141)
  2. 2022 (145)
  3. 2021 (129)
  4. 2020 (128)
  5. 2019 (125)
  6. 2018 (109)

More Years

Publications
  1. Annals of Oncology (1101)
Publishers
  1. Oxford University Press (1101)

Results (1101)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV + P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Kim, D. W.; Goto, K.; Schram, A.; Hollebecque, A.; Rha, S. Y.; Nishino, K.; Duruisseaux, M.; Umemoto, K.; Park, J. O.; Leighl, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Kelly, W. K.; Danila, D. C.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P. J.; Armstrong, A. J.; Pook, D. W.; Kim, M.; Dorff, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
    Meeting Abstract

    Chou, H. I.; Lu, L.; Chung, C. T.; Chan, J. S. K.; Chan, R. N. C.; Lee, Y. H. A.; Dee, E. C.; Ng, K.; Pui, H. H. H.; Lee, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2— , locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; van Cutsem, E.; Gallego Plazas, J.; Huang, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Oh, D. Y.; Janjigian, Y. Y.; Al-Batran, S. E.; Wainberg, Z. A.; van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Omori, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, S. L.; Sangro, B.; Kelley, R. K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E. N.; Furuse, J.; Kang, Y. K.; Galle, P. R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
    Meeting Abstract

    Yoshino, T.; André, T.; Kim, T. W.; Yong, W. P.; Shiu, K. K.; Vittrup Jensen, B.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
    Meeting Abstract

    Oh, D. Y.; Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Banerjee, S.; Gonzalez Martin, A.; Jung, K. H.; Lugowska, I.; Manso, L. M.; Manzano, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save